152 related articles for article (PubMed ID: 35315085)
1. Pepsinogen/Proton Pump Co-Expression in Barrett's Esophageal Cells Induces Cancer-Associated Changes.
Stabenau KA; Samuels TL; Lam TK; Mathison AJ; Wells C; Altman KW; Battle MA; Johnston N
Laryngoscope; 2023 Jan; 133(1):59-69. PubMed ID: 35315085
[TBL] [Abstract][Full Text] [Related]
2. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
3. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
5. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
6. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
7. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
8. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
9. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
11. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease.
Greene CL; Worrell SG; DeMeester TR
Ann Surg; 2015 Dec; 262(6):910-24. PubMed ID: 25822684
[TBL] [Abstract][Full Text] [Related]
12. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
13. The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
Blaine-Sauer S; Samuels TL; Yan K; Johnston N
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047737
[TBL] [Abstract][Full Text] [Related]
14. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
Spechler SJ
Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
[TBL] [Abstract][Full Text] [Related]
15. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
16. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
17. From Reflux Esophagitis to Esophageal Adenocarcinoma.
Souza RF
Dig Dis; 2016; 34(5):483-90. PubMed ID: 27331918
[TBL] [Abstract][Full Text] [Related]
18. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.
Stein HJ; Kauer WK; Feussner H; Siewert JR
J Gastrointest Surg; 1998; 2(4):333-41. PubMed ID: 9841990
[TBL] [Abstract][Full Text] [Related]
19. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
20. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.
Lv J; Guo L; Liu JJ; Zhao HP; Zhang J; Wang JH
World J Gastroenterol; 2019 May; 25(18):2149-2161. PubMed ID: 31143067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
